Anne Wojcicki thought she might be able to get the FDA off by her back if 23andMe stopped advertising its $99 genetic testing kits. But when your company is five years late on "analytical and clinical" studies that prove your product does what it promises and ignored the agency's questions for five months, they're not inclined to shrug it off.
It's hard out there for a rule-flouting, heavily financed disruptor. If it's not government regulators, then it's "frivolous lawsuits," amirite? This time, it's a class action lawsuit filed in California accusing 23andMe of "falsely and misleadingly" advertising their $99 genetic tests. The complaint, which asks for at least $5 million, also says the tests are "not supported by any scientific evidence."